Protara Therapeutics 주식 (NASDAQ: TARA)

에 대한 최신 뉴스 Protara Therapeutics (NASDAQ:TARA) 주식

Protara Therapeutics

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

$BTC

MARA

MSTR

ORCL

ROKU

SOUN

TARA

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 프로타라, 마라, 트레이드 데스크, 사운드하운드 AI 및 오라클

Biotech

Health Care

Exclusives

Tech

Trading Ideas

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다. 투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics Inc

Taraxa

Tarachi Gold Corp

TARANIS RESOURCES INC ORD by Taranis Resources Inc.

Taranis Resources Inc

WIIM

POET

POET Technologies shares are trading lower after the company announced a $25 million offering consisting of 5 million units at $5.00 per share.

News

IPOs

TTAN

ServiceTitan IPO Indicating $113.60/Share; IPO Priced At $71/Share On 8.8M Shares

Morgan Stanley analyst Toni Kaplan maintains Waste Connections (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCN#NYSE">WCN</a>) with a Overweight and raises the price target from $206 to $214.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Waste Connections, Raises Price Target to $214

INTC

Intel Exec Says Doesn't Make Sense If Foundry And Products Business "Completely Separated And There's No Tie"; Complete Separation Of Foundry And Product Business Is "An Open Question"

Macro Economic Events

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower following worse-than-expected inflation data.

Morgan Stanley analyst Toni Kaplan maintains S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Overweight and raises the price target from $570 to $595.

SPGI

Morgan Stanley Maintains Overweight on S&P Global, Raises Price Target to $595

<a href="https://www.theinformation.com/briefings/youtube-tv-hikes-prices-by-10-per-month">https://www.theinformation.com/briefings/youtube-tv-hikes-prices-by-10-per-month</a>
YouTube said the price of the base plan for YouTube TV will go up to $82.99 per month, effective immediately for new subscribers (with the changes going into effect for most existing subscribers next month). It attributed the price increase to "the rising cost of content."

GOOG

GOOGL

'YouTube TV Hikes Prices By $10 Per Month" - The Information

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and maintains $90 price target.

Reiteration

BMRN

Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $90 Price Target

Morgan Stanley analyst Toni Kaplan maintains TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) with a Overweight and raises the price target from $119 to $130.

Morgan Stanley Maintains Overweight on TransUnion, Raises Price Target to $130

Citigroup analyst Stephen Trent maintains American Airlines Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) with a Buy and raises the price target from $19 to $23.

Citigroup Maintains Buy on American Airlines Gr, Raises Price Target to $23

Deep-pocketed investors have adopted a bearish approach towards Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LMT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Lockheed Martin. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 30% leaning bullish and 50% bearish. Among these notable options, 4 are puts, totaling $141,995, and 6 are calls, amounting to $294,124.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $450.0 to $560.0 for Lockheed Martin over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Lockheed Martin stands at 380.0, with a total volume reaching 466.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Lockheed Martin, situated within the strike price corridor from $450.0 to $560.0, throughout the last 30 days.
<h3>Lockheed Martin Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734022000_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.6</td>
<td>$4.8</td>
<td>$5.6</td>
<td>$560.00</td>
<td>$67.2K</td>
<td align="right">290</td>
<td align="right">122</td>
</tr>
<tr>
<td>LMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.6</td>
<td>$11.3</td>
<td>$11.6</td>
<td>$560.00</td>
<td>$63.8K</td>
<td align="right">77</td>
<td align="right">62</td>
</tr>
<tr>
<td>LMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.5</td>
<td>$11.6</td>
<td>$11.6</td>
<td>$560.00</td>
<td>$56.8K</td>
<td align="right">77</td>
<td align="right">135</td>
</tr>
<tr>
<td>LMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$67.6</td>
<td>$64.1</td>
<td>$67.3</td>
<td>$500.00</td>
<td>$53.8K</td>
<td align="right">47</td>
<td align="right">13</td>
</tr>
<tr>
<td>LMT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$19.1</td>
<td>$16.9</td>
<td>$18.3</td>
<td>$450.00</td>
<td>$47.5K</td>
<td align="right">221</td>
<td align="right">26</td>
</tr>
</tbody>
</table>

<h3>About Lockheed Martin</h3>
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Lockheed's largest segment is aeronautics, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.
After a thorough review of the options trading surrounding Lockheed Martin, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Lockheed Martin Standing Right Now?</h3>
<ul>
<li>With a trading volume of 695,248, the price of LMT is down by -1.4%, reaching $497.17.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 40 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Lockheed Martin</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $543.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Lockheed Martin, maintaining a target price of $543. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lockheed Martin options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Lockheed Martin Unusual Options Activity For December 12

Financial giants have made a conspicuous bullish move on Snowflake. Our analysis of options history for Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) revealed 26 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 42% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $549,304, and 21 were calls, valued at $1,323,564.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $200.0 for Snowflake over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Snowflake's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Snowflake's whale activity within a strike price range from $100.0 to $200.0 in the last 30 days. 
<h3>Snowflake Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734021994_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$18.15</td>
<td>$18.0</td>
<td>$18.0</td>
<td>$187.50</td>
<td>$160.2K</td>
<td>570</td>
<td>475</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$18.5</td>
<td>$17.9</td>
<td>$18.0</td>
<td>$187.50</td>
<td>$158.4K</td>
<td>570</td>
<td>385</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$35.65</td>
<td>$34.5</td>
<td>$34.5</td>
<td>$155.00</td>
<td>$138.0K</td>
<td>279</td>
<td>40</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$10.0</td>
<td>$9.65</td>
<td>$10.0</td>
<td>$175.00</td>
<td>$124.0K</td>
<td>1.6K</td>
<td>124</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$3.7</td>
<td>$3.5</td>
<td>$3.7</td>
<td>$175.00</td>
<td>$110.9K</td>
<td>509</td>
<td>2.5K</td>
</tr>
</tbody>
</table>

<h3>About Snowflake</h3>
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that went public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to buy and ingest data, while its data solutions can be hosted on various public clouds.
Following our analysis of the options activities associated with Snowflake, we pivot to a closer look at the company's own performance.
<h3>Snowflake's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,012,643, with SNOW's price down by -0.89%, positioned at $170.43.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 76 days.</li>
</ul>
<h3>What Analysts Are Saying About Snowflake</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $186.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Outperform rating for Snowflake, targeting a price of $220. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Snowflake with a target price of $188. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Snowflake, which currently sits at a price target of $150. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Snowflake, targeting a price of $185. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Snowflake, targeting a price of $190. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Snowflake, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

SNOW

Snowflake Unusual Options Activity

Deep-pocketed investors have adopted a bullish approach towards Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Hut 8. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 52% leaning bullish and 28% bearish. Among these notable options, 3 are puts, totaling $108,900, and 18 are calls, amounting to $745,093.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $45.0 for Hut 8 during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Hut 8 options trades today is 1227.31 with a total volume of 8,578.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Hut 8's big money trades within a strike price range of $20.0 to $45.0 over the last 30 days.
<h3>Hut 8 Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734021989_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.0</td>
<td>$2.89</td>
<td>$4.0</td>
<td>$28.00</td>
<td>$80.4K</td>
<td>822</td>
<td align="right">216</td>
</tr>
<tr>
<td>HUT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$12.0</td>
<td>$11.65</td>
<td>$11.65</td>
<td>$20.00</td>
<td>$69.9K</td>
<td>156</td>
<td align="right">60</td>
</tr>
<tr>
<td>HUT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$1.24</td>
<td>$1.23</td>
<td>$1.24</td>
<td>$30.00</td>
<td>$62.0K</td>
<td>2.0K</td>
<td align="right">546</td>
</tr>
<tr>
<td>HUT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.5</td>
<td>$11.5</td>
<td>$11.5</td>
<td>$30.00</td>
<td>$48.3K</td>
<td>1.2K</td>
<td align="right">10</td>
</tr>
<tr>
<td>HUT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$2.3</td>
<td>$2.29</td>
<td>$2.3</td>
<td>$30.00</td>
<td>$47.6K</td>
<td>937</td>
<td align="right">654</td>
</tr>
</tbody>
</table>

<h3>About Hut 8</h3>
Hut 8 Corp is engaged in the mining of digital assets with an operational focus on utilizing specialized equipment to solve complex computational problems to validate transactions on the Bitcoin blockchain and receiving Bitcoin in return for successful services. The company has four reportable business segments: Digital Assets Mining, Managed Services, High Performance Computing -Colocation and Cloud, and Other. It derives maximum revenue from Digital Assets Mining segment.
After a thorough review of the options trading surrounding Hut 8, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Hut 8</h3>
<ul>
<li>Currently trading with a volume of 9,394,593, the HUT's price is up by 5.25%, now at $28.09. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 105 days.</li>
</ul>
<h3>What Analysts Are Saying About Hut 8</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $32.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Jones Trading downgraded its rating to Buy, setting a price target of $36. 
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on Hut 8, which currently sits at a price target of $32. 
&#x2A; Maintaining their stance, an analyst from Craig-Hallum continues to hold a Buy rating for Hut 8, targeting a price of $32. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Hut 8, targeting a price of $32. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Hut 8, targeting a price of $32. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hut 8 options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Market Whales and Their Recent Bets on HUT Options

Morgan Stanley analyst Dara Mohsenian maintains ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Equal-Weight and raises the price target from $46 to $50.

Morgan Stanley Maintains Equal-Weight on ODDITY Tech, Raises Price Target to $50

Intel Exec Says TSMC Is The "Benchmark For What's Expected In The Industry"

On a November episode of The Steam Room, hosted by Ernie Johnson and Charles Barkley, the duo welcomed entrepreneur and Dallas Mavericks owner <a href="https://www.benzinga.com/startups/24/09/41082417/to-mark-cuban-theres-no-doubt-donald-trumps-billionaire-tech-backers-know-they-can-manipulate-him-be">Mark Cuban</a> for a candid conversation about politics, leadership and the state of the world. The conversation got real fast, especially when Ernie asked Cuban if he'd ever seriously considered running for office.
"I did a little bit, you know, four years ago in 2020," Cuban admitted. "I even talked to a pollster and then I talked to my family. We took a family vote and they said, ‘Hell no.'"
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
</ul>
Cuban explained that his family had no interest in the toll that a campaign and public scrutiny would take. "My kids are like, ‘We don't want to. No, we just don't want to deal with it.' And it's even – it's gotten meaner, you know. It's not gotten easier; it's gotten meaner. And, you know, just the hate on social media. And if your kids live on social media, why would I put them through that?"
Instead, Cuban has focused his energy on <a href="https://www.benzinga.com/personal-finance/24/07/39799717/patients-pay-the-price-as-drug-middlemen-profit-says-ftc-report-mark-cubans-take-anyone-surprise">initiatives like Cost Plus Drugs</a>, his company aimed at lowering prescription drug prices. "With Cost Plus Drugs and other things I'm doing, I think I can have an impact that really helps this country," he said. "So, you know, I can stay focused on those things and help where I can."
See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Ernie then steered the conversation toward the larger issue of division in the country, asking Cuban, "Hey Mark, how do you heal division?" Cuban, as always, got straight to the point.
"You know, it's a leadership issue. It really, really is. It takes somebody who wants to bring people together," he said. "You've got to be somebody who can walk into any situation in any town in America and sit and have a beer, coffee, tea, whatever it is or go to their kitchen table and explain how much more alike we are than different."
Cuban reflected on how <a href="https://www.benzinga.com/personal-finance/24/07/39821566/dave-ramsey-slams-instagram-rich-your-fancy-friends-are-probably-broke">social media amplifies division</a>, contrasting it with real-life interactions. "You guys see it," he said. "There are times when you're getting into it on social media or someone's giving you a hard time on social media and then you run into that person in real life and you're friends. You get along great and you know, you shake hands, give each other a hug, whatever it is. And so, we're so much more alike than people realize."
Trending: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Charles chimed in and <a href="https://www.benzinga.com/personal-finance/24/09/40985018/mark-cubans-black-amex-card-was-declined-trying-to-buy-a-140-000-bottle-of-champagne-after-his-n">Cuban highlighted</a> what makes Barkley special. "That's why Charles is so good at this. Charles can talk to anybody, you know and put himself in any circumstance and get along with everybody," Cuban said. "I think that's what we need."
Then Ernie asked if Mark Cuban and Charles Barkley ever run together on the same ticket?
Cuban didn't miss a beat: "We'd win. Yes. Absolutely yes. We would win running away. No question about it."
By the end of the episode, it was clear that while neither Cuban nor Barkley is jumping into politics anytime soon, they've both thought deeply about what real leadership looks like. And if they ever did decide to run? Well, let's just say they'd already have Ernie as their campaign manager.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Mark Cuban Is Confident He And Charles Barkley Could Win A Presidential Election If They Ran Together – 'No Question About It'

H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 5.41% on an annualized basis producing an average annual return of 19.09%. Currently, H&amp;R Block has a market capitalization of $7.72 billion. 
Buying $1000 In HRB: If an investor had bought $1000 of HRB stock 5 years ago, it would be worth $2,401.89 today based on a price of $56.32 for HRB at the time of writing.
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734021916_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In H&R Block 5 Years Ago Would Be Worth This Much Today

Maxim Group analyst Jason McCarthy initiates coverage on Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) with a Buy rating and announces Price Target of $8.

Initiation

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Maxim Group Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $8

Intel Exec Says "We Need A Much Better ROI For The Investment That We've Made"

Jones Trading analyst Stephen Glagola initiates coverage on Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy rating and announces Price Target of $36.

Jones Trading Initiates Coverage On Hut 8 with Buy Rating, Announces Price Target of $36

The latest update is out from Protara Therapeutics ( ($TARA) ). Protara Therapeutics presented promising interim results from its Phase 2 ADVANCED-...

Protara Therapeutics Reports Promising Phase 2 Trial Results

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Protara Therapeutics (TARA – Research Report), with a price...

Promising Efficacy of TARA-002 Positions Protara Therapeutics as a Compelling Buy for HR-NMIBC Treatment

Protara announces proposed offering of common stock

Protara Therapeutics (TARA) announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of issuing co...

Protara Therapeutics announces common stock offering, no amount given

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – C3.ai (AI)&nbsp;up 3.9% Vail ...

Closing Bell Movers: Oracle slips 8% after Q2 earnings miss, disappointing guide

Protara Therapeutics drops 6%, prices $100M offering

The deal range was $6.00-$6.50. TD Cowen, Cantor Fitzgerald, LifeSci Capital, Oppenheimer and Scotiabank acted as joint book running managers for t...

Protara Therapeutics 13.69M share Spot Secondary priced at $6.25

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Protara Therapeutics: Carving New Roads In Bladder Cancer

An announcement from Protara Therapeutics ( ($TARA) ) is now available. Protara Therapeutics has announced the closing of a public offering of comm...

Protara Therapeutics Raises $100M in Stock Offering

ASYS

BMEA

BRZE

CASY

CMRX

FLNC

YEXT

Press Releases

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Earnings

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Financing

Protara Announces Proposed Public Offering

Protara Announces Pricing of $100 Million Public Offering

Protara Announces Closing of $100 Million Public Offering

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Aligos Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cibus

Elutia

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Immunic

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Leap Therapeutics

MediciNova

Monopar Therapeutics

Puma Biotechnology

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Regulus Therapeutics

Skye Bioscience

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Vaxart

X4 Pharmaceuticals

Guggenheim

HC Wainwright & Co.

Oppenheimer

매주,&nbsp;벤징가의&nbsp;스톡 위스퍼 지수(Benzinga's Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목</a>을 받을 만한 주식 5종목을 소개한다.



투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.



다음은 12월 6일 주간 벤징가 ‘스톡 위스퍼' 지수의 개요:



1. 프로타라 테라퓨틱스&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>):



프로타라의 주가는 회사가 ADVANCED-2 시험의 2단계 결과를 보고한 후 <a href="https://www.benzinga.com/24/12/42343355/why-is-protara-therapeutics-stock-skyrocketing-over-100-on-thursday" target="_blank" rel="noreferrer noopener">이번 주에 급등</a>했다. 침습성 방광암을 표적으로 하는 TARA-002에 대한 임상시험은 많은 환자들에게 완전한 반응을 보였다.



회사는 제25차 비뇨기종양학회 연례회의에서 이 결과를 보고했다. 프로타라는 2025년 중반에 임상시험을 위해 12개월간 평가 가능한 환자의 데이터를 보고할 예정이다.



프로타라 테라퓨틱스의 CEO 제시 셰퍼먼(Jesse Shefferman)은 &#8220;우리는 국제적인 사이트 확장과 함께 이러한 고무적인 데이터가 환자 등록을 가속화할 것이라고 믿으며 2025년 중반에 12개월 평가 가능한 환자의 초기 데이터를 보고할 수 있기를 기대한다&#8221;고 말했다.



아래 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120624&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a> 차트는 한 주 동안 급등한 주가를 보여줍니다. 프로타라 주가는 지난 5일 101.02% 급등했다. 2024년 현재까지 181% 이상 상승했다.



<figure class="wp-block-image"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06101858/Screenshot-260.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" alt=""/></figure>



2. 마라 홀딩&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>):



비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격이 <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42336184/exclusive-bitcoin-crossing-100000-is-a-defining-moment-experts-say" target="_blank" rel="noreferrer noopener">100,000달러를 넘어 치솟았</a>고 회사 업데이트로 인해 마라 홀딩스는 이번 주 동안 독자들의 큰 관심을 끌 수 있었다. 이 회사는 최근 11월에 907개의 비트코인을 채굴했다고 <a href="https://www.benzinga.com/24/12/42267974/whats-going-on-with-bitcoin-mining-stock-mara-holdings-monday" target="_blank" rel="noreferrer noopener">공유</a>했는데, 이는 전월 대비 26% 증가한 수치이다. 2024년에 회사는 8,563개의 비트코인을 채굴했다.



마라의 CEO 프레드 티엘(Fred Thiel)은 &#8220;11월은 마라에게 기록적인 달이었다. 우리의 채굴 작업은 추가 채굴기의 성공적인 배치와 향상된 운영 효율성에 힘입어 전례 없는 수준의 생산량을 달성했다&#8221;고 말했다.



또한 회사는 기존 전환사채를 구매하고 추가 비트코인을 획득하는 데 사용할 7억 달러의 0% 전환선순위 채권을 제공할 <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42265676/mara-targets-btc-and-debt-buybacks-with-new-700m-convertible-notes-offering-mstrs-michael-saylor-says-it-is-a-company-on-the-bitcoin-standard" target="_blank" rel="noreferrer noopener">계획을 발표</a>했다. 추가 비트코인을 구매하기 위한 컨버터블 노트 전략은 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)가 해왔던 전략과 유사하다.



마이크로스트레티지의 회장 마이클 세일러는 마라가 &#8220;비트코인 표준을 따르는 회사&#8221;라고 말했다.



11월 30일 현재 마라는 34,959개의 비트코인을 보유하고 있어 상장 기업 중 가장 큰 보유자 중 하나이다.



<figure class="wp-block-image"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06101916/Screenshot-262.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" alt=""/></figure>



3. 더 트레이드 데스크 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>):



로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)와의 합병 추측으로 인해 트레이드 데스크 주가가 <a href="https://www.benzinga.com/news/24/12/42342085/why-trade-desk-ttd-stock-is-up-8-this-week" target="_blank" rel="noreferrer noopener">이번 주에 급등</a>했고 벤징가 독자들의 관심을 얻었다.



구겐하임의 분석가들은 트레이드 데스크의 광고 플랫폼과 로쿠의 스트리밍 공간을 결합하고 연결된 TV 공간에서 거대 기업을 만들 두 회사 간의 합병 사례를 제시했다. 구겐하임의 분석가들은 합병으로 인한 이익이 위험보다 더 클 것이며 합병된 회사는 아마존이나 알파벳과 같은 회사에 비해 더 나은 경쟁자가 될 것이라고 말했다.



합병 추측은 트레이드 데스크가 스마트 TV 제조업체와 협력하여 배포할 계획인 벤츄라(Ventura) <a href="https://www.benzinga.com/24/11/42097269/the-trade-desk-launches-ventura-transforming-streaming-tv-advertising" target="_blank" rel="noreferrer noopener">스트리밍 운영 체제</a>를 공개한 지 한 달도 채 되지 않아 나온 것이다. 벤츄라는 이르면 2025년 출시될 예정이다.



트레이드 데스크에서는 최근 스코샤 은행이 부문별 아웃퍼폼(Outperform) 등급과 133달러 목표 가격으로 커버리지를 시작한 것을 포함하여 <a href="https://www.benzinga.com/quote/TTD/analyst-ratings" target="_blank" rel="noreferrer noopener">여러 분석가의 메모</a>를 확인했다. 맥쿼리는 아웃퍼폼 투자의견을 유지하고 목표주가를 133달러에서 150달러로 상향 조정했다. 에버코어 ISI는 아웃퍼폼 등급을 유지하고 목표 가격을 110달러에서 135달러로 높였다.



<figure class="wp-block-image"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06101932/Screenshot-264.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" alt=""/></figure>



4. 사운드하운드 AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>):



인공지능(AI) 관련 회사는 이번 주 동안 독자들의 관심이 높아졌으며, 올해 들어 주식 621% 이상 급등했다.



회사가 추가 레스토랑에 음성 AI 스마트 주문 시스템을 <a href="https://www.benzinga.com/24/12/42348247/soundhound-ai-shares-were-on-the-rise-today-whats-going-on" target="_blank" rel="noreferrer noopener">배포한다고 발표</a>한 후 주가가 상승했다. 회사의 AI 기반 레스토랑 솔루션은 전화, 키오스크, 드라이브스루 및 헤드셋 주문 시스템을 지원하는 기술을 통해 전 세계 10,000개 이상의 위치에서 사용되고 있다. 이 회사는 또한 최근 아멜리아(Amelia 대화형) AI 에이전트가 2024년에 100,000건 이상의 고객 통화를 처리하여 고객의 운영 효율성을 지원했다고 밝혔다.



사운드하운드 주가는 2024년에도 계속해서 높게 거래되고 있으며, 회사가 11월 3분기 재무 보고서를 보고한 직후에 나온 주에 60% 이상 상승했다. 회사는 2024년과 2025년 모두 연간 수익 전망을 높였으며 앞으로 투자자들은 주식을 면밀히 모니터링할 것이다.



<figure class="wp-block-image"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06101949/Screenshot-265.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" alt=""/></figure>



5. 오라클클 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>):



투자자들의 큰 관심을 받고 있는 또 다른 주식은 회사의 2분기 재무 결과를 앞둔 오라클이다.



오라클은 월요일 시장 마감 후 2분기 실적을 발표할 예정이다. 분석가들은 이 회사가 지난해 2분기 1.34달러에서 증가한 1.48달러의 주당 순이익을 보고할 것으로 예상하고 있다. 회사는 8분기 연속 주당순이익이 분석가 추정치를 상회했다. 분석가들은 회사가 지난해 2분기의 129억 달러보다 증가한 141억 달러의 분기 매출을 보고할 것으로 예상하고 있다.



회사는 최근 주당 이익에 있어 일련의 좋은 결과를 얻었지만 수익 예측을 깨는 데 어려움을 겪었다. 회사는 지난 10개 분기 중 단 4개 분기에서만 분석가의 예상 매출을 넘어섰다.



웨드부시의 분석가 댄 아이브스는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42307179/salesforce-palantir-and-oracle-spearhead-an-ai-revolution-says-wedbushs-dan-ives-a-renaissance-of-growth" target="_blank" rel="noreferrer noopener">최근</a> 오라클이 2025년에 &#8216;AI 혁명&#8217;의 혜택을 누릴 것이라고 말했다. 분석가들은 분기별 재무 결과를 앞두고 오라클 주식에 대한 <a href="https://www.benzinga.com/quote/ORCL/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격을 높여</a>&nbsp;왔다.



<figure class="wp-block-image"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06102005/Screenshot-266.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" alt=""/></figure>



다음 주 보고서를 계속 지켜봐 주시기 바랍니다.&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">여기에서</a>&nbsp;Benzinga Pro를 팔로우하여 모든 최신 헤드라인과 시장을 움직이는 주요 기사를 확인하세요.



여기에서 최근 ‘스톡 위스퍼 지수' 보고서를 읽어보세요.



<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%82%AC%EC%9D%B4%EB%A8%BC-%ED%94%84%EB%A1%9C%ED%8D%BC%ED%8B%B0-%EC%95%A8%EB%A6%AC/" target="_blank" rel="noreferrer noopener">11월 30일</a></li>



<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EB%8D%B8%ED%83%80-%ED%95%AD%EA%B3%B5-%EB%82%98%EC%9D%B4%ED%82%A4-%EC%98%A4%ED%86%A0/" target="_blank" rel="noreferrer noopener">11월 23일</a></li>



<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%95%A1%EC%86%90-%EC%8A%A4%EB%85%B8%EC%9A%B0%ED%94%8C%EB%A0%88%EC%9D%B4-%EC%97%A0/" target="_blank" rel="noreferrer noopener">11월 16일</a></li>



<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%9D%B8%EC%8A%A4%EB%A9%94%EB%93%9C-%EC%9D%B8%ED%8A%9C%EC%9D%B4%ED%8B%B0%EB%B8%8C/" target="_blank" rel="noreferrer noopener">11월 9일</a></li>



<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%95%A0%EC%A7%88%EB%9F%B0%ED%8A%B8-%ED%8A%B8%EB%A0%88%EC%9D%B4%EB%93%9C/" target="_blank" rel="noreferrer noopener">11월 2일</a></li>
</ul>



다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다.&nbsp;<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

벤징가의 '스톡 위스퍼' 지수: 프로타라, 마라, 트레이드 데스크, 사운드하운드 AI 및 오라클

매주, 벤징가의 스톡 위스퍼 지수(Benzinga's Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목</a>을 받을 만한 주식 5종목을 소개한다.
투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.
다음은 12월 6일 주간 벤징가 ‘스톡 위스퍼' 지수의 개요:
1. 프로타라 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>):
프로타라의 주가는 회사가 ADVANCED-2 시험의 2단계 결과를 보고한 후 <a href="https://www.benzinga.com/24/12/42343355/why-is-protara-therapeutics-stock-skyrocketing-over-100-on-thursday" target="_blank" rel="noopener">이번 주에 급등</a>했다. 침습성 방광암을 표적으로 하는 TARA-002에 대한 임상시험은 많은 환자들에게 완전한 반응을 보였다.
회사는 제25차 비뇨기종양학회 연례회의에서 이 결과를 보고했다. 프로타라는 2025년 중반에 임상시험을 위해 12개월간 평가 가능한 환자의 데이터를 보고할 예정이다.
프로타라 테라퓨틱스의 CEO 제시 셰퍼먼(Jesse Shefferman)은 &#8220;우리는 국제적인 사이트 확장과 함께 이러한 고무적인 데이터가 환자 등록을 가속화할 것이라고 믿으며 2025년 중반에 12개월 평가 가능한 환자의 초기 데이터를 보고할 수 있기를 기대한다&#8221;고 말했다.
아래 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120624&amp;t=be2bearmibe3na1" target="_blank" rel="noopener">Benzinga Pro</a> 차트는 한 주 동안 급등한 주가를 보여줍니다. 프로타라 주가는 지난 5일 101.02% 급등했다. 2024년 현재까지 181% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06101858/Screenshot-260.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
2. 마라 홀딩 (NASDAQ:<a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>):
비트코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD">BTC</a>) 가격이 <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42336184/exclusive-bitcoin-crossing-100000-is-a-defining-moment-experts-say" target="_blank" rel="noopener">100,000달러를 넘어 치솟았</a>고 회사 업데이트로 인해 마라 홀딩스는 이번 주 동안 독자들의 큰 관심을 끌 수 있었다. 이 회사는 최근 11월에 907개의 비트코인을 채굴했다고 <a href="https://www.benzinga.com/24/12/42267974/whats-going-on-with-bitcoin-mining-stock-mara-holdings-monday" target="_blank" rel="noopener">공유</a>했는데, 이는 전월 대비 26% 증가한 수치이다. 2024년에 회사는 8,563개의 비트코인을 채굴했다.
마라의 CEO 프레드 티엘(Fred Thiel)은 &#8220;11월은 마라에게 기록적인 달이었다. 우리의 채굴 작업은 추가 채굴기의 성공적인 배치와 향상된 운영 효율성에 힘입어 전례 없는 수준의 생산량을 달성했다&#8221;고 말했다.
또한 회사는 기존 전환사채를 구매하고 추가 비트코인을 획득하는 데 사용할 7억 달러의 0% 전환선순위 채권을 제공할 <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42265676/mara-targets-btc-and-debt-buybacks-with-new-700m-convertible-notes-offering-mstrs-michael-saylor-says-it-is-a-company-on-the-bitcoin-standard" target="_blank" rel="noopener">계획을 발표</a>했다. 추가 비트코인을 구매하기 위한 컨버터블 노트 전략은 마이크로스트레티지(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/mstr" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for MSTR">MSTR</a>)가 해왔던 전략과 유사하다.
마이크로스트레티지의 회장 마이클 세일러는 마라가 &#8220;비트코인 표준을 따르는 회사&#8221;라고 말했다.
11월 30일 현재 마라는 34,959개의 비트코인을 보유하고 있어 상장 기업 중 가장 큰 보유자 중 하나이다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06101916/Screenshot-262.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
3. 더 트레이드 데스크 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>):
로쿠(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/roku" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ROKU">ROKU</a>)와의 합병 추측으로 인해 트레이드 데스크 주가가 <a href="https://www.benzinga.com/news/24/12/42342085/why-trade-desk-ttd-stock-is-up-8-this-week" target="_blank" rel="noopener">이번 주에 급등</a>했고 벤징가 독자들의 관심을 얻었다.
구겐하임의 분석가들은 트레이드 데스크의 광고 플랫폼과 로쿠의 스트리밍 공간을 결합하고 연결된 TV 공간에서 거대 기업을 만들 두 회사 간의 합병 사례를 제시했다. 구겐하임의 분석가들은 합병으로 인한 이익이 위험보다 더 클 것이며 합병된 회사는 아마존이나 알파벳과 같은 회사에 비해 더 나은 경쟁자가 될 것이라고 말했다.
합병 추측은 트레이드 데스크가 스마트 TV 제조업체와 협력하여 배포할 계획인 벤츄라(Ventura) <a href="https://www.benzinga.com/24/11/42097269/the-trade-desk-launches-ventura-transforming-streaming-tv-advertising" target="_blank" rel="noopener">스트리밍 운영 체제</a>를 공개한 지 한 달도 채 되지 않아 나온 것이다. 벤츄라는 이르면 2025년 출시될 예정이다.
트레이드 데스크에서는 최근 스코샤 은행이 부문별 아웃퍼폼(Outperform) 등급과 133달러 목표 가격으로 커버리지를 시작한 것을 포함하여 <a href="https://www.benzinga.com/quote/TTD/analyst-ratings" target="_blank" rel="noopener">여러 분석가의 메모</a>를 확인했다. 맥쿼리는 아웃퍼폼 투자의견을 유지하고 목표주가를 133달러에서 150달러로 상향 조정했다. 에버코어 ISI는 아웃퍼폼 등급을 유지하고 목표 가격을 110달러에서 135달러로 높였다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06101932/Screenshot-264.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
4. 사운드하운드 AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>):
인공지능(AI) 관련 회사는 이번 주 동안 독자들의 관심이 높아졌으며, 올해 들어 주식 621% 이상 급등했다.
회사가 추가 레스토랑에 음성 AI 스마트 주문 시스템을 <a href="https://www.benzinga.com/24/12/42348247/soundhound-ai-shares-were-on-the-rise-today-whats-going-on" target="_blank" rel="noopener">배포한다고 발표</a>한 후 주가가 상승했다. 회사의 AI 기반 레스토랑 솔루션은 전화, 키오스크, 드라이브스루 및 헤드셋 주문 시스템을 지원하는 기술을 통해 전 세계 10,000개 이상의 위치에서 사용되고 있다. 이 회사는 또한 최근 아멜리아(Amelia 대화형) AI 에이전트가 2024년에 100,000건 이상의 고객 통화를 처리하여 고객의 운영 효율성을 지원했다고 밝혔다.
사운드하운드 주가는 2024년에도 계속해서 높게 거래되고 있으며, 회사가 11월 3분기 재무 보고서를 보고한 직후에 나온 주에 60% 이상 상승했다. 회사는 2024년과 2025년 모두 연간 수익 전망을 높였으며 앞으로 투자자들은 주식을 면밀히 모니터링할 것이다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06101949/Screenshot-265.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
5. 오라클클 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>):
투자자들의 큰 관심을 받고 있는 또 다른 주식은 회사의 2분기 재무 결과를 앞둔 오라클이다.
오라클은 월요일 시장 마감 후 2분기 실적을 발표할 예정이다. 분석가들은 이 회사가 지난해 2분기 1.34달러에서 증가한 1.48달러의 주당 순이익을 보고할 것으로 예상하고 있다. 회사는 8분기 연속 주당순이익이 분석가 추정치를 상회했다. 분석가들은 회사가 지난해 2분기의 129억 달러보다 증가한 141억 달러의 분기 매출을 보고할 것으로 예상하고 있다.
회사는 최근 주당 이익에 있어 일련의 좋은 결과를 얻었지만 수익 예측을 깨는 데 어려움을 겪었다. 회사는 지난 10개 분기 중 단 4개 분기에서만 분석가의 예상 매출을 넘어섰다.
웨드부시의 분석가 댄 아이브스는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42307179/salesforce-palantir-and-oracle-spearhead-an-ai-revolution-says-wedbushs-dan-ives-a-renaissance-of-growth" target="_blank" rel="noopener">최근</a> 오라클이 2025년에 &#8216;AI 혁명&#8217;의 혜택을 누릴 것이라고 말했다. 분석가들은 분기별 재무 결과를 앞두고 오라클 주식에 대한 <a href="https://www.benzinga.com/quote/ORCL/analyst-ratings" target="_blank" rel="noopener">목표 가격을 높여</a> 왔다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06102005/Screenshot-266.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
다음 주 보고서를 계속 지켜봐 주시기 바랍니다. <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">여기에서</a> Benzinga Pro를 팔로우하여 모든 최신 헤드라인과 시장을 움직이는 주요 기사를 확인하세요.
여기에서 최근 ‘스톡 위스퍼 지수' 보고서를 읽어보세요.
<ul class="block core-block">
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%82%AC%EC%9D%B4%EB%A8%BC-%ED%94%84%EB%A1%9C%ED%8D%BC%ED%8B%B0-%EC%95%A8%EB%A6%AC/" target="_blank" rel="noopener">11월 30일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EB%8D%B8%ED%83%80-%ED%95%AD%EA%B3%B5-%EB%82%98%EC%9D%B4%ED%82%A4-%EC%98%A4%ED%86%A0/" target="_blank" rel="noopener">11월 23일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%95%A1%EC%86%90-%EC%8A%A4%EB%85%B8%EC%9A%B0%ED%94%8C%EB%A0%88%EC%9D%B4-%EC%97%A0/" target="_blank" rel="noopener">11월 16일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%9D%B8%EC%8A%A4%EB%A9%94%EB%93%9C-%EC%9D%B8%ED%8A%9C%EC%9D%B4%ED%8B%B0%EB%B8%8C/" target="_blank" rel="noopener">11월 9일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%95%A0%EC%A7%88%EB%9F%B0%ED%8A%B8-%ED%8A%B8%EB%A0%88%EC%9D%B4%EB%93%9C/" target="_blank" rel="noopener">11월 2일</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Protara Therapeutics

뉴스

에 대한 최신 뉴스 Protara Therapeutics (NASDAQ:TARA) 주식

토요일, 12월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌